Jaarverslag 2006 - Department of Respiratory Medicine of the ...

11. Haegens A, Vernooy JHJ, Wouters EFM. Contribution of myeloperoxidase to inflammatory processes in
lung epithelial cells. ERJ 2006;28 suppl.50: 853S.
12. Haegens A, Vernooy JHJ, Mossman BT, Wouters EFM. Myeloperoxidase -/- mice show decreased lung
neutrophilia and increased epithelial cell proliferation after lipopolysaccharide or asbestos exposure. ERJ
2006;28 suppl.50: 398S.
13. Heijckmann AC, Huijberts MSP, de Vries J, Wolffenbuttel BHR, Geusens P. Drent M. Fractures, bone
mineral density and bone turnover in a dutch sarcoidosis population. Osteoporosis int 2006; 17 (suppl 2):
S182/P618 MO.
14. Heijckmann AC, Huijberts MSP, de Vries J, Wolffenbuttel BHR, Geusens P. Drent M. Fractures, bone
mineral density and bone turnover in a dutch sarcoidosis population. Osteoporosis Int 2006; 17 (Suppl 1);
S40/P174.
15. Jonker G, Michielsen HJ, King TE, de Vries J, Drent M. Fatigue in sarcoidosis: American versus Dutch
sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:154.
16. Jonker G, van Kroonenburgh M, Smulders N, Halders S, de Vries J, Drent M. I-MIBG kinetics in the lung in
sarcoidosis. Indicator of autonomic nerve dysfunction? Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:155.
17. Judson MA, Baughman RP, Kavuru M, Costabel U, Drent M, Du Bois RM. Improvement in 6 minute walk
distance in a double-blind randomized placebo-controlled trial of infliximab for chronic pulmonary
sarcoidosis. Am J Respir Crit Care Med 2006; 173: A722.
18. Langen RCJ, Haegens A, Kelders MCJM, Vernooy JHJ, Wouters EFM, Schols. Atrophy and increased
expression of MuRF1 and atrogin in skeletal muscle following acute pulmonary inflammation. ERJ 2006;28
suppl.50: 622S.
19. Mercken EM, Hageman GJ, Houben JMJ, Moonen HJ, Broekhuizen R, Bast A, Wouters EFM, Schols AMWJ.
Pulmonary cachexia and the oxidant/antioxidant balance. ERJ 2006;28 suppl.50: 653S.
20. Moller TM, Spruit MA, Does JD, Pennings HJ, Janssen PP, Wouters EFM. Baseline self-reported
comorbidity in COPD patients referred for pulmonary rehabilitation. ERJ 2006;28 suppl.50: 532S.
21. Moller TM, Spruit MA, Pennings HJ, Does JD, Janssen PP, Wouters EFM. Self-reported comorbidity and Creactive
protein in patients with COPD. ERJ 2006;28 suppl.50: 116S.
22. Pillai SG, Lake S Lomas D, Rennard S, Pare P, Claverley P, Vestbo J, Wouters E, Agusti A, Donner C,
Make B, Warren L, Anderson W, Silverman E. Linkage analysis of quantitative spirometric measurements
in COPD families. AJRCCM 2006; A216.
23. Silver EK, Lake SL, Lomas DA, Rennard SI, Pare PD, Claverley PM, Vestbo J, Wouters EF, Agusti AG,
Donner CF, Make BJ, Anderson WH, Pillai SG, Coxson HO, Bosten MA. Phenotypes in chronic
obstructive pulmonary disease. AJRCCM 2006; A620.
24. Spuit MA, Janssen PP, Schols AMWJ, Wouters EFM. Changes in bone mineral density and fat-free mass
following pulmonary rehabilitation in patients with COPD. ERJ 2006;28 suppl.50: 607S.
25. Spruit MA, Janssen PP, Fransen LGM, Janssen JJW, Akkermans MA, Wouters EFM. Disabilities experienced
in normal dialy activities by patients with COPD. ERJ 2006;28 suppl.50: 629S.
26. Spruit MA, Janssen PP, Willemsen SCP, Hochstenbag MMH, Wouters EFM. Pulmonary function and
exercise capacity before and after an8-week multidisciplinary inpatient rehabilitation program in COPD
patients. ERJ 2006;28 suppl.50: 331S.
27